A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

Inclusion Criteria: * Provide written informed consent prior to any study-related procedures. * Be 18 years of age or older. * Have at least a 2 year history of moderate to severe allergic conjunctivitis. * Have a positive skin prick test to ragweed within the past 12 months of Screening (Visit 1A). * Have a score of ≥ 2 for staff-assessed ocular redness in at least one region (nasal or temporal) in each eye and ≥ 2 for subject-assessed ocular itching within the 3.5-hour period of allergen exposure in the EEC at Visit 1B. * Have required more than one anti-allergy pharmaceutical treatments in the past 2 years to treat ocular symptoms (including oral, topical, nasal treatments). * Be able to self-administer topical ophthalmic drops. * Avoid any topical or systemic ocular medications during the entire study period. * Are willing and able to follow instructions and can be present for the required study visits for the duration of the study. Exclusion Criteria: * Are female and of childbearing potential and unwilling to remain abstinent through 30 days following the last dose of study drug or not willing to use acceptable birth control methods. * Have previously used an IL-1 blocker (e.g., Anakinra, Rilonacept, or Ilaris). * Have a known contraindication or hypersensitivities to Anakinra (Kineret®) or any therapeutic agent targeted to IL-1 or any component of study drug formulation. * Current participation in another clinical study involving an experimental treatment or participation in such a study within 30 days prior to study entry. * Require concomitant use of TNF-blocking agents (e.g., Etanercept, Adalimumab, Infliximab). * Have a history of glaucoma or intraocular pressure (IOP) \> 25 mmHg at the Visit 1A (Medical Screening) or a history of elevated IOP within the past year. * Have had ocular surgery including laser procedures within the past 12 months of Visit 1A (Medical Screening). * Have had contact lens wear within 4 weeks prior to Visit 1A (Medical Screening) or unwilling to discontinue wear during the study period